Fitzsimons Innovation Community Member

Pathways Bioscience’s technology improves healthspan and overcomes health and wellness problems associated with aging.

TBX-2400 is expected to improve engraftment and reconstitution of immune system for patients receiving Hematopoietic Stem Cell Transplants.

Amie Krause, Senior Vice President and Chief People Officer, and Kristin Yarema, Chief Commercial Officer, of Atara Biotherapeutics, discuss women in leadership positions in pharma and the effects of a gender diverse company.

The Gates Biomanufacturing Facility announced a continued strategic agreement with Nkarta, Inc. to manufacture clinical supply of therapeutic Natural Killer (NK) cells.

Aurora, Colo.-based Foresight Diagnostics, which was co-founded in 2020 by Jake Chabon, PhD, Max Diehn, MD, PhD, Ash Alizadeh, MD, PhD, and David Kurtz, MD PhD, has developed a new liquid biopsy test that can identify the earliest hint of cancer recurrence.

Three-year contract leading to advance clinical trials for Lassa Fever vaccines reaffirms Zalgen’s focus on preparedness and its dedication to developing solutions for emerging viral threats.

Cerebral Therapeutics, clinical-stage pharmaceutical company developing innovative treatments for neurological disease, has appointed Guy Anthony as Chief Financial Officer.

The company will present clinical data of industry-leading Minimal Residual Disease (MRD) technology in lymphoma and lung cancer.